Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – What’s Next?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $29.16, but opened at $27.49. Chugai Pharmaceutical shares last traded at $28.88, with a volume of 34,048 shares changing hands.

Analyst Ratings Changes

CHGCY has been the topic of a number of analyst reports. Smbc Nikko Sec. raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a research report on Wednesday, February 25th. UBS Group raised Chugai Pharmaceutical to a “strong-buy” rating in a report on Tuesday, January 27th. Two equities research analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Strong Buy”.

Chugai Pharmaceutical Stock Performance

The firm’s 50 day moving average price is $29.08 and its 200-day moving average price is $26.11. The firm has a market capitalization of $95.01 billion, a PE ratio of 33.18 and a beta of 0.60.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings data on Thursday, January 29th. The company reported $0.25 EPS for the quarter. Chugai Pharmaceutical had a return on equity of 22.00% and a net margin of 34.47%.The business had revenue of $2.25 billion during the quarter. On average, equities research analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.